F8 and hemophilia A: According to current guidelines of the World Federation of Hemophilia, the standard of care for hemophilia A patients is treatment with FVIII concentrates4; both recombinant FVIII (rFVIII) or plasma‐derived FVIII (pdFVIII) products are available, and factor replacement therapy may be administered in an episodic or prophylactic manner.4